Exploring Sickle Cell Disease: An Integrative Analysis of Literary Evidence, Clinical Insights, Patient Case Studies, and Pharmacovigilance Perspectives

Abstract

Sickle Cell Disease (SCD) is a hereditary hemoglobin disorder associated with significant morbidity, recurrent hospitalizations, and reduced quality of life, particularly in developing countries like India. The present study aims to explore SCD through an integrative approach combining literature evidence, clinical insights, patient case analysis, and pharmacovigilance perspectives, along with assessment of public awareness using a questionnaire-based survey. The study was designed as a descriptive and analytical research work incorporating both secondary and primary data. Secondary data were collected from published scientific literature, textbooks, and clinical reports to understand the genetic basis, pathophysiology, clinical manifestations, and therapeutic approaches of SCD. Primary data were obtained through a structured online survey to evaluate awareness regarding the disease, its symptoms, treatment, and pharmacovigilance concepts among participants. Findings from literature analysis confirmed that SCD is a multisystem disorder characterized by vaso-occlusion, chronic hemolysis, and progressive organ damage. Therapeutic approaches such as hydroxyurea, blood transfusion, and newer agents like voxelotor and crizanlizumab have improved disease management, although challenges in accessibility and adherence persist. The case study analysis highlighted real-world clinical challenges including poor treatment adherence, socioeconomic barriers, and crisis triggers such as dehydration. Survey results indicated moderate general awareness of SCD; however, detailed knowledge regarding complications, treatment safety, and pharmacovigilance was found to be limited. A significant proportion of participants were unaware of formal adverse drug reaction monitoring systems, indicating a gap in public health education. In conclusion, SCD requires a multidisciplinary management approach integrating clinical care, patient education, and pharmacovigilance practices. Strengthening awareness programs, improving access to treatment, and promoting medication safety monitoring are essential to enhance patient outcomes and reduce disease burden.